Undertreatment or Overtreatment in the Adjuvant Setting for M1 No Evidence of Disease in Renal Cell Carcinoma: A Clinical Conundrum
European Urology Focus · 2025
DOI: 10.1016/j.euf.2025.04.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2025. Verfasst von Wesley Yip und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA. Electronic address: wyip@coh.org. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Overtreatment, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Guidelines recommend consideration of 1 yr of adjuvant pembrolizumab for selected patients with oligometastatic renal cell carcinoma who are disease-free after metastasectomy. Owing to the heterogeneity of this population, it is unclear whether patients would benefit more from single-agent pembrolizumab or from observation and salvage therapy with multiagent regimens. Better prognostic biomarkers are needed to guide treatment decisions in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA. Electronic address: wyip@coh.org.
- Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Zitieren
APA
Yip, W., & Rini, B. I. (2025). Undertreatment or Overtreatment in the Adjuvant Setting for M1 No Evidence of Disease in Renal Cell Carcinoma: A Clinical Conundrum. European Urology Focus. https://doi.org/10.1016/j.euf.2025.04.009
Vancouver
Yip W, Rini BI. Undertreatment or Overtreatment in the Adjuvant Setting for M1 No Evidence of Disease in Renal Cell Carcinoma: A Clinical Conundrum. European Urology Focus. 2025. doi:10.1016/j.euf.2025.04.009
BibTeX
@article{Yip2025,
author = {Yip, Wesley and Rini, Brian I},
title = {Undertreatment or Overtreatment in the Adjuvant Setting for M1 No Evidence of Disease in Renal Cell Carcinoma: A Clinical Conundrum},
journal = {European Urology Focus},
year = {2025},
doi = {10.1016/j.euf.2025.04.009}
}
EUVIMED